JP2015521202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521202A5 JP2015521202A5 JP2015515176A JP2015515176A JP2015521202A5 JP 2015521202 A5 JP2015521202 A5 JP 2015521202A5 JP 2015515176 A JP2015515176 A JP 2015515176A JP 2015515176 A JP2015515176 A JP 2015515176A JP 2015521202 A5 JP2015521202 A5 JP 2015521202A5
- Authority
- JP
- Japan
- Prior art keywords
- ica
- positive
- pnag
- pga
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000052769 pathogen Species 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 73
- 230000001717 pathogenic effect Effects 0.000 claims description 71
- 150000004676 glycans Chemical class 0.000 claims description 67
- 229920001282 polysaccharide Polymers 0.000 claims description 67
- 239000005017 polysaccharide Substances 0.000 claims description 67
- 239000008194 pharmaceutical composition Substances 0.000 claims description 65
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 29
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 29
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 23
- 241000304886 Bacilli Species 0.000 claims description 19
- 241000222122 Candida albicans Species 0.000 claims description 12
- 241000233866 Fungi Species 0.000 claims description 12
- 241001138501 Salmonella enterica Species 0.000 claims description 12
- 229940095731 candida albicans Drugs 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 244000045947 parasite Species 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 6
- 241000228212 Aspergillus Species 0.000 claims description 6
- 241000606124 Bacteroides fragilis Species 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 6
- 241000589876 Campylobacter Species 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 6
- 241000949031 Citrobacter rodentium Species 0.000 claims description 6
- 241000193163 Clostridioides difficile Species 0.000 claims description 6
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 6
- 241000194033 Enterococcus Species 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 6
- 241000223218 Fusarium Species 0.000 claims description 6
- 241000589989 Helicobacter Species 0.000 claims description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 6
- 241000186781 Listeria Species 0.000 claims description 6
- 201000009906 Meningitis Diseases 0.000 claims description 6
- 241000588653 Neisseria Species 0.000 claims description 6
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 6
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 6
- 241000607626 Vibrio cholerae Species 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 238000007910 systemic administration Methods 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- 201000008827 tuberculosis Diseases 0.000 claims description 6
- 241000283073 Equus caballus Species 0.000 claims description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 5
- 238000009629 microbiological culture Methods 0.000 claims description 5
- 241000607142 Salmonella Species 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 210000005056 cell body Anatomy 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 230000016784 immunoglobulin production Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 230000000850 deacetylating effect Effects 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 108010067770 Endopeptidase K Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000988 Lysostaphin Proteins 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 239000003637 basic solution Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000004915 pus Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000004989 spleen cell Anatomy 0.000 claims description 2
- 210000004988 splenocyte Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 241000009328 Perro Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- -1 lymph Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653389P | 2012-05-30 | 2012-05-30 | |
| US61/653,389 | 2012-05-30 | ||
| US201361827661P | 2013-05-26 | 2013-05-26 | |
| US61/827,661 | 2013-05-26 | ||
| PCT/US2013/043283 WO2013181348A1 (en) | 2012-05-30 | 2013-05-30 | Polysaccharide compositions and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017186345A Division JP6663402B2 (ja) | 2012-05-30 | 2017-09-27 | 多糖組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521202A JP2015521202A (ja) | 2015-07-27 |
| JP2015521202A5 true JP2015521202A5 (enExample) | 2016-07-21 |
| JP6403667B2 JP6403667B2 (ja) | 2018-10-10 |
Family
ID=49673891
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515176A Active JP6403667B2 (ja) | 2012-05-30 | 2013-05-30 | 多糖組成物およびその使用 |
| JP2017186345A Active JP6663402B2 (ja) | 2012-05-30 | 2017-09-27 | 多糖組成物およびその使用 |
| JP2018229987A Pending JP2019059763A (ja) | 2012-05-30 | 2018-12-07 | 多糖組成物およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017186345A Active JP6663402B2 (ja) | 2012-05-30 | 2017-09-27 | 多糖組成物およびその使用 |
| JP2018229987A Pending JP2019059763A (ja) | 2012-05-30 | 2018-12-07 | 多糖組成物およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20150165016A1 (enExample) |
| EP (1) | EP2854822B1 (enExample) |
| JP (3) | JP6403667B2 (enExample) |
| KR (1) | KR102282726B1 (enExample) |
| CN (2) | CN110464839A (enExample) |
| AU (4) | AU2013267444A1 (enExample) |
| BR (1) | BR112014030025A2 (enExample) |
| CA (2) | CA3241764A1 (enExample) |
| CL (1) | CL2014003276A1 (enExample) |
| DK (1) | DK2854822T3 (enExample) |
| ES (1) | ES2826000T3 (enExample) |
| HK (1) | HK1209031A1 (enExample) |
| IL (1) | IL235968B (enExample) |
| MX (2) | MX2014014649A (enExample) |
| NZ (1) | NZ703260A (enExample) |
| PH (1) | PH12014502680A1 (enExample) |
| RU (2) | RU2014152261A (enExample) |
| SG (3) | SG10201911609XA (enExample) |
| WO (1) | WO2013181348A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101062525B1 (ko) * | 2002-11-12 | 2011-09-06 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 포도상구균 감염에 대한 다당류 백신 |
| EP2455402A1 (en) | 2004-04-21 | 2012-05-23 | The Brigham and Women's Hospital, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
| JP5555230B2 (ja) | 2008-07-21 | 2014-07-23 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | β−１，６−グルコサミンオリゴ糖を合成するための方法および組成物 |
| WO2016069888A1 (en) | 2014-10-29 | 2016-05-06 | University Of Wyoming | Compositions and methods for making and using hydrolytic enzymes for degrading polysaccharides made by foodborne pathogenic bacteria |
| SI3506935T1 (sl) | 2016-09-02 | 2024-06-28 | Sanofi Pasteur, Inc. | Cepivo proti neisseriji meningitidis |
| CA3101239A1 (en) * | 2018-05-23 | 2019-11-28 | Meharry Medical College | Glycan strand or oligosaccharide derived from gram-positive bacteria, method of making thereof and use thereof for inhibiting hiv or hbv replication (formerly: molecules derived from gram-positive bacteria) |
| US12397014B2 (en) | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
| CN110638830A (zh) * | 2019-09-29 | 2020-01-03 | 深圳市生命谷生命科技研究院 | 消化泥鳅多糖调节免疫功能或治疗免疫相关疾病的用途 |
| US11173199B2 (en) | 2019-11-13 | 2021-11-16 | Alopexx Inc. | Low contaminant compositions |
| IL293091A (en) * | 2019-11-22 | 2022-07-01 | Alopexx Inc | Methods for providing continuous therapy against pnag comprising microbes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2046920B1 (enExample) | 1969-06-19 | 1974-05-03 | Citizen Watch Co Ltd | |
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5565354A (en) | 1986-09-05 | 1996-10-15 | Sandoz Ltd. | Production of human monoclonal antibodies specific for hepatitis B surface antigen |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| ATE400296T1 (de) * | 1999-12-02 | 2008-07-15 | Novartis Vaccines & Diagnostic | Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung |
| KR101062525B1 (ko) * | 2002-11-12 | 2011-09-06 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 포도상구균 감염에 대한 다당류 백신 |
| EP2455402A1 (en) * | 2004-04-21 | 2012-05-23 | The Brigham and Women's Hospital, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
| JP5555230B2 (ja) | 2008-07-21 | 2014-07-23 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | β−１，６−グルコサミンオリゴ糖を合成するための方法および組成物 |
| US12397014B2 (en) * | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
-
2013
- 2013-05-30 EP EP13798089.2A patent/EP2854822B1/en active Active
- 2013-05-30 CN CN201910419108.7A patent/CN110464839A/zh active Pending
- 2013-05-30 NZ NZ703260A patent/NZ703260A/en not_active IP Right Cessation
- 2013-05-30 US US14/404,303 patent/US20150165016A1/en not_active Abandoned
- 2013-05-30 SG SG10201911609XA patent/SG10201911609XA/en unknown
- 2013-05-30 KR KR1020147036646A patent/KR102282726B1/ko not_active Expired - Fee Related
- 2013-05-30 SG SG11201500428XA patent/SG11201500428XA/en unknown
- 2013-05-30 ES ES13798089T patent/ES2826000T3/es active Active
- 2013-05-30 JP JP2015515176A patent/JP6403667B2/ja active Active
- 2013-05-30 SG SG10201609902YA patent/SG10201609902YA/en unknown
- 2013-05-30 DK DK13798089.2T patent/DK2854822T3/da active
- 2013-05-30 RU RU2014152261A patent/RU2014152261A/ru not_active Application Discontinuation
- 2013-05-30 CA CA3241764A patent/CA3241764A1/en active Pending
- 2013-05-30 HK HK15109685.4A patent/HK1209031A1/xx unknown
- 2013-05-30 CA CA2879592A patent/CA2879592C/en active Active
- 2013-05-30 MX MX2014014649A patent/MX2014014649A/es unknown
- 2013-05-30 BR BR112014030025A patent/BR112014030025A2/pt not_active IP Right Cessation
- 2013-05-30 CN CN201380040356.1A patent/CN104602696A/zh active Pending
- 2013-05-30 AU AU2013267444A patent/AU2013267444A1/en not_active Abandoned
- 2013-05-30 WO PCT/US2013/043283 patent/WO2013181348A1/en not_active Ceased
- 2013-05-30 RU RU2019101166A patent/RU2019101166A/ru unknown
-
2014
- 2014-11-27 IL IL235968A patent/IL235968B/en active IP Right Grant
- 2014-11-28 MX MX2019006620A patent/MX2019006620A/es unknown
- 2014-11-28 CL CL2014003276A patent/CL2014003276A1/es unknown
- 2014-12-01 PH PH12014502680A patent/PH12014502680A1/en unknown
-
2017
- 2017-09-27 JP JP2017186345A patent/JP6663402B2/ja active Active
-
2018
- 2018-03-14 AU AU2018201798A patent/AU2018201798A1/en not_active Abandoned
- 2018-12-07 JP JP2018229987A patent/JP2019059763A/ja active Pending
-
2020
- 2020-02-07 AU AU2020200908A patent/AU2020200908A1/en not_active Abandoned
-
2022
- 2022-03-02 AU AU2022201447A patent/AU2022201447B2/en active Active
-
2023
- 2023-12-01 US US18/526,557 patent/US20240358811A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521202A5 (enExample) | ||
| Abdullahi et al. | Intrigues of biofilm: A perspective in veterinary medicine | |
| RU2014152261A (ru) | Композиции полисахаридов и способы применения | |
| Abdolmohammadi Khiav et al. | Vaccination against pathogenic clostridia in animals: A review | |
| Morais et al. | Next-generation whole-cell pneumococcal vaccine | |
| Kang et al. | In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT | |
| Rossi et al. | Protective effect of oral administration of transgenic tobacco seeds against verocytotoxic Escherichia coli strain in piglets | |
| JP2006513166A5 (enExample) | ||
| Krüger et al. | Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows | |
| Zhang et al. | A combined Clostridium perfringens/Trueperella pyogenes inactivated vaccine induces complete immunoprotection in a mouse model | |
| Rossi et al. | Translational approach to induce and evaluate Verocytotoxic E. coli O138 based disease in piglets | |
| Alabdullah et al. | Evaluation of the efficacy of a cholera toxin-based staphylococcus aureus vaccine against bovine intramammary challenge | |
| Orth et al. | Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans | |
| Raheem et al. | The probiotic potential of Lactobacillus plantarum strain RW1 isolated from canine faeces | |
| Xu et al. | Effects of Enterotoxigenic Escherichia coli challenge on Jejunal morphology and microbial community profiles in weaned crossbred piglets | |
| Girard et al. | Use of virulence factor-specific egg yolk-derived immunoglobulins as a promising alternative to antibiotics for prevention of attaching and effacing Escherichia coli infections | |
| Pors et al. | Outer membrane vesicles of Gallibacterium anatis induce protective immunity in egg-laying hens | |
| Awad et al. | The sialidase NanS enhances non-TcsL mediated cytotoxicity of Clostridium sordellii | |
| JP2018511303A5 (enExample) | ||
| Goldwater | Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome | |
| Rossi et al. | Tobacco seed-based oral vaccination against verocytotoxic O138 Escherichia coli as alternative approach to antibiotics in weaned piglets | |
| FARAHMAND et al. | Identification of Toxic Shock Syndrome Toxin-1 (TSST-1) gene in Staphylococcus aureus isolated from bovine mastitis milk | |
| US20110129479A1 (en) | Immunogen selection directed in immunoglobulin packages in plasma and colostrum and method of making and using same | |
| Townsend et al. | The neonatal intestinal microbial flora, immunity, and infections | |
| Samanta | Veterinary bacteriology |